Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | GAA | P10253 | 2/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | NOS3 | P29474 | 1/20 | 0.42 |
| ▸ | NOS1 | P29475 | 1/20 | 0.42 |
| ▸ | NOS2 | P35228 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | MMP8 | P22894 | 1/20 | 0.40 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.39 |
| ▸ | UHRF1 | Q96T88 | 1/20 | 0.38 |
| ▸ | CCR1 | P32246 | 1/20 | 0.38 |
| ▸ | CCR5 | P51681 | 1/20 | 0.38 |
| ▸ | CCR8 | P51685 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13044634 | 0.84 | SMN1; SMN2 (0.43) | SMN1; SMN2MEN1KMT2AGAANPC1 | |
| SCHEMBL10528852 | 0.81 | SMN1; SMN2 (0.42) | SMN1; SMN2MEN1KMT2AGAANPC1 | |
| SCHEMBL1604959 | 0.80 | GAA (0.55) | SMN1; SMN2MEN1KMT2AGAANOS3 | |
| SCHEMBL15999192 | 0.78 | SMN1; SMN2 (0.39) | SMN1; SMN2MEN1KMT2AGAANPC1 | |
| SCHEMBL1162993 | 0.78 | SMN1; SMN2 (0.66) | SMN1; SMN2MEN1KMT2AGAANPC1 | |
| SCHEMBL17331878 | 0.76 | CASP1 (0.49) | SMN1; SMN2MEN1KMT2AGAANPC1 | |
| SCHEMBL13044641 | 0.75 | NOS3 (0.42) | SMN1; SMN2MEN1KMT2AGAANPC1 | |
| SCHEMBL1433150 | 0.75 | SMN1; SMN2 (0.43) | SMN1; SMN2MEN1KMT2AGAANPC1 | |
| SCHEMBL17427962 | 0.75 | HTT (0.44) | SMN1; SMN2MEN1KMT2AGAARAB9A | |
| SCHEMBL12985766 | 0.75 | MEN1 (0.43) | SMN1; SMN2MEN1KMT2AGAARAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9809588-B2 | GLS1 inhibitors for treating disease | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2017-11-07 | — | — | US | disclosed |
| US-20170291895-A1 | GLS1 INHIBITORS FOR TREATING DISEASE | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2017-10-12 | — | — | US | disclosed |
| US-20160009704-A1 | GLS1 INHIBITORS FOR TREATING DISEASE | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2016-01-14 | — | — | US | disclosed |
| US-20080227796-A1 | 7-Amino-6-Hetaryl-1,2,4-Triazolo[1,5-A]Pyrimidine Compounds and the Use Thereof for Controlling Pathogenic Fungi | BASF AKTIENGESELLSCHAFT (DE) | 2008-09-18 | — | — | US | disclosed |
| CN-101080409-A | 7-amino-6-hetaryl-1,2,4-triazolo[1,5-a]pyrimidine compounds and the use thereof for controlling pathogenic fungi | BASF AG (DE) | 2007-11-28 | — | — | CN | disclosed |
| EP-1828191-A2 | 7-AMINO-6-HETARYL-1,2,4-TRIAZOLO[1,5-A]PYRIMIDINE COMPOUNDS AND THE USE THEREOF FOR CONTROLLING PATHOGENIC FUNGI | BASF AKTIENGESELLSCHAFT (DE) | 2007-09-05 | — | — | EP | disclosed |
| WO-2006122740-A2 | 7-AMINO-6-HETARYLIMIDAZOLO[1,2-A]PYRIMIDINE COMPOUNDS AND USE THEREOF FOR CONTROLLING HARMFUL FUNGI | BASF AKTIENGESELLSCHAFT (DE) | 2006-11-23 | — | — | WO | disclosed |
| WO-2006066818-A2 | 7-AMINO-6-HETARYL-1,2,4-TRIAZOLO[1,5-A]PYRIMIDINE COMPOUNDS AND THE USE THEREOF FOR CONTROLLING PATHOGENIC FUNGI | BASF AKTIENGESELLSCHAFT (DE) | 2006-06-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160009704-A1 | GLS1 INHIBITORS FOR TREATING DISEASE | GLS2, GLS, GLG1 | SMN1; SMN2 2191/4885MEN1 1849/4885KMT2A 2651/4885 |
| US-20170291895-A1 | GLS1 INHIBITORS FOR TREATING DISEASE | GLS2, GLS, GLG1 | SMN1; SMN2 2191/4885MEN1 1849/4885KMT2A 2651/4885 |
| US-20080227796-A1 | 7-Amino-6-Hetaryl-1,2,4-Triazolo[1,5-A]Pyrimidine Compounds and the Use Thereof for Controlling Pathogenic Fungi | CYP8B1, CBR3, HDHD5 | SMN1; SMN2 4798/4885MEN1 3812/4885KMT2A 3561/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.